+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Polycystic Ovarian Syndrome Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030

  • PDF Icon

    Report

  • 175 Pages
  • September 2021
  • Region: Global
  • The Business Research Company
  • ID: 5446166
Polycystic Ovarian Syndrome Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global polycystic ovarian syndrome treatment market.







This report focuses on the polycystic ovarian syndrome treatment market which is experiencing strong growth. The report gives a guide to the polycystic ovarian syndrome treatment market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for polycystic ovarian syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Polycystic Ovarian Syndrome Treatment market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider polycystic ovarian syndrome treatment market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The polycystic ovarian syndrome treatment market section of the report gives context. It compares the polycystic ovarian syndrome treatment market with other segments of the polycystic ovarian syndrome treatment market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, polycystic ovarian syndrome treatment indicators comparison.

Scope


Markets Covered:


  • By Drug Type: Oral Contraceptives; Ornithine Decarboxylase Inhibitors; Insulin-Sensitizing Agents; Anti-Depressants; Diuretics; Aromatase Inhibitors
  • By Surgery Type: Ovarian Wedge Resection; Laparoscopic Ovarian Drilling
  • By End User: Hospitals & Clinics; Ambulatory Surgical Centers; Diagnostic Centers; Gynecology Centers; Feminist Health Centers

Companies Mentioned:


Bristol-Myer Squibb Company; Bayer AG; Pfizer, Inc.; Merck KGaA; Sanofi

Countries:


Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia

Regions:


Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Polycystic Ovarian Syndrome Treatment Market

What is the estimated value of the Global Polycystic Ovarian Syndrome Treatment Market?

The Global Polycystic Ovarian Syndrome Treatment Market was estimated to be valued at $3.96 billion in 2021.

What is the growth rate of the Global Polycystic Ovarian Syndrome Treatment Market?

The growth rate of the Global Polycystic Ovarian Syndrome Treatment Market is 4.7%, with an estimated value of $4.76 billion by 2025.

What is the forecasted size of the Global Polycystic Ovarian Syndrome Treatment Market?

The Global Polycystic Ovarian Syndrome Treatment Market is estimated to be worth $4.76 billion by 2025.

Who are the key companies in the Global Polycystic Ovarian Syndrome Treatment Market?

Key companies in the Global Polycystic Ovarian Syndrome Treatment Market include Bristol, Myer Squibb Company, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi, AstraZeneca, Novartis AG and Abbott.

Table of Contents

1. Executive Summary2. Polycystic Ovarian Syndrome Treatment Market Characteristics3. Polycystic Ovarian Syndrome Treatment Market Trends and Strategies4. Impact Of COVID-19 On Polycystic Ovarian Syndrome Treatment
5. Polycystic Ovarian Syndrome Treatment Market Size and Growth
5.1. Global Polycystic Ovarian Syndrome Treatment Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Polycystic Ovarian Syndrome Treatment Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Polycystic Ovarian Syndrome Treatment Market Segmentation
6.1. Global Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral Contraceptives
  • Ornithine Decarboxylase Inhibitors
  • Insulin-Sensitizing Agents
  • Anti-Depressants
  • Diuretics
  • Aromatase Inhibitors
6.2. Global Polycystic Ovarian Syndrome Treatment Market, Segmentation by Surgery Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Ovarian Wedge Resection
  • Laparoscopic Ovarian Drilling
6.3. Global Polycystic Ovarian Syndrome Treatment Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Gynecology Centers
  • Feminist Health Centers

7. Polycystic Ovarian Syndrome Treatment Market Regional and Country Analysis
7.1. Global Polycystic Ovarian Syndrome Treatment Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Polycystic Ovarian Syndrome Treatment Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market
8.1. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Polycystic Ovarian Syndrome Treatment Market
9.1. China Polycystic Ovarian Syndrome Treatment Market Overview
9.2. China Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Polycystic Ovarian Syndrome Treatment Market
10.1. India Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Polycystic Ovarian Syndrome Treatment Market
11.1. Japan Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Polycystic Ovarian Syndrome Treatment Market
12.1. Australia Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Polycystic Ovarian Syndrome Treatment Market
13.1. Indonesia Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Polycystic Ovarian Syndrome Treatment Market
14.1. South Korea Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Polycystic Ovarian Syndrome Treatment Market
15.1. Western Europe Polycystic Ovarian Syndrome Treatment Market Overview
15.2. Western Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Polycystic Ovarian Syndrome Treatment Market
16.1. UK Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Polycystic Ovarian Syndrome Treatment Market
17.1. Germany Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Polycystic Ovarian Syndrome Treatment Market
18.3. France Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Polycystic Ovarian Syndrome Treatment Market
19.1. Eastern Europe Polycystic Ovarian Syndrome Treatment Market Overview
19.2. Eastern Europe Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Polycystic Ovarian Syndrome Treatment Market
20.1. Russia Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Polycystic Ovarian Syndrome Treatment Market
21.1. North America Polycystic Ovarian Syndrome Treatment Market Overview
21.2. North America Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Polycystic Ovarian Syndrome Treatment Market
22.1. USA Polycystic Ovarian Syndrome Treatment Market Overview
22.2. USA Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Polycystic Ovarian Syndrome Treatment Market
23.1. South America Polycystic Ovarian Syndrome Treatment Market Overview
23.2. South America Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Polycystic Ovarian Syndrome Treatment Market
24.1. Brazil Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Polycystic Ovarian Syndrome Treatment Market
25.1. Middle East Polycystic Ovarian Syndrome Treatment Market Overview
25.2. Middle East Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Polycystic Ovarian Syndrome Treatment Market
26.1. Africa Polycystic Ovarian Syndrome Treatment Market Overview
26.2. Africa Polycystic Ovarian Syndrome Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Polycystic Ovarian Syndrome Treatment Market Competitive Landscape and Company Profiles
27.1. Polycystic Ovarian Syndrome Treatment Market Competitive Landscape
27.2. Polycystic Ovarian Syndrome Treatment Market Company Profiles
27.2.1. Bristol-Myer Squibb Company
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bayer AG
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Pfizer, Inc.
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Merck KGaA
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Sanofi
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Polycystic Ovarian Syndrome Treatment Pipeline Analysis29. Key Mergers and Acquisitions in the Polycystic Ovarian Syndrome Treatment Market30. Polycystic Ovarian Syndrome Treatment Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer

Executive Summary

Major players in the polycystic ovarian syndrome treatment market are Bristol-Myer Squibb Company, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott and Addex Therapeutics Ltd.

The global polycystic ovarian syndrome treatment market is expected to grow from $3.67 billion in 2020 to $3.96 billion in 2021 at a compound annual growth rate (CAGR) of 7.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.76 billion in 2025 at a CAGR of 5%.

The polycystic ovarian syndrome treatment market consists of sale of services and related products that are used in hospital pharmacies, drug stores, and retail pharmacies to treat polycystic ovarian syndrome. The polycystic ovarian syndrome is a disorder in which hormones are out of control for females and have male hormones that are higher than normal, which causes them to skip menstrual periods and makes pregnancy more difficult for them.

The polycystic ovarian syndrome treatment market covered in this report is segmented by drug type into oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, aromatase inhibitors. It is also segmented by surgery type into ovarian wedge resection and laparoscopic ovarian drilling and by end user into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Lack of drugs approved by regulatory bodies such as FDA (Food and Drug Administration) among many countries is a key factor hampering the growth of the polycystic ovarian syndrome treatment market. FDA has not approved pharmacological treatment for use in adolescents with PCOS. However, some pharmacological interventions are used to treat PCOS symptoms. For instance, rimonabant, a key appetite suppressant cannabinoid CB1 receptor antagonist was not approved by the United States Food and Drug Administration (FDA) in the USA due to concerns about suicidal ideation and drug overdoses. Moreover, Minoxidil is the only drug approved by FDA, used for the treatment of female pattern baldness. Therefore, the lack of regulatory body approved drugs in many countries is a key factor restraining the growth of the polycystic ovarian syndrome treatment market.

In July 2019, Eurolife Healthcare Pvt. Ltd, a Mumbai based company, manufactures and distributes an exclusive portfolio of healthcare formulations, Intravenous Infusions, Ophthalmic, Sterilized water for Injections, Nebules, Tablets, Capsules, Ointment & Creams, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition helped the company to tap and service its European and the US markets for intravenous infusions in a better way. Teva Pharmaceutical Industries Ltd., a multinational pharmaceutical company, develops, manufactures, and markets generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients.

The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS is a prevalent hormonal disorder among premenopausal women worldwide, with reproductive, endocrine, and metabolic abnormalities. The PCOS prevalence ranges from 2.2% to 26% globally and is highly variable. In China, the figures range between 2% to 7.5% and 6.3% in Sri Lanka, 9.13% in south India and 22.5% in Maharashtra. The rise in genetic and hormonal disorders globally is expected to increase the growth of the polycystic ovarian syndrome treatment market.

Laparoscopic ovarian drilling is a major trend driving the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a surgical treatment performed by the doctors in critical conditions that can cause ovulation in women with polycystic ovary syndrome (PCOS). Ovarian drilling is often used by women with PCOS who often do not ovulate despite having attempted weight loss and use of fertility drugs. According to the study published in 2019 by the Department of Gynecology and Obstetrics in major hospitals in France, after laparoscopic drilling, 47.4% (137 patients) had pregnancy and 51.8% (71 patients) of these were spontaneous. 16.6% (48 patients) women had at least two pregnancies after drilling and 56.3% (27 patients) of these were spontaneous. 33 women received second drillings. Of these, 57.6% (19 patients) achieved at least one pregnancy, within this 52.6% (10 patients) were spontaneous.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bristol-Myer Squibb Company
  • Bayer AG
  • Pfizer Inc.
  • Merck KGaA
  • Sanofi
  • AstraZeneca
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Abbott
  • Addex Therapeutics Ltd
  • BIOCAD
  • Allergan plc
  • Johnson and Johnson
  • Ferring BV
  • Ferring Pharmaceuticals Inc.

Methodology

Loading
LOADING...